骨肉瘤化疗耐药相关机制的研究进展
陈金泉1
张世权2
1.518035 深圳市第二人民医院、深圳大学医学院第一附属医院骨肿瘤中心;511436 广州医科大学研究生院2.518035,深圳市第二人民医院、深圳大学医学院第一附属医院骨肿瘤中心
摘要：Osteosarcoma is the most common primary cancer derived from bone tissues, which is frequently found in adolescents and children. The extensive application of the comprehensive limb salvage treatment reduces the amputation rate significantly, and the five-year survival rate is higher. But the prognosis of chemotherapy-resistant patients is still poor. It is very important to improve the prognosis of osteosarcoma by clarifying the pathogenesis of drug resistance. In this paper, we review the mechanism of osteosarcoma chemoresistance, including the non-coding RNA disorders, gene, DNA repair, cancer stem cells, autophagy and tumor microenvironment ect. We also summarize the deficiencies in the current studies about osteosarcoma chemoresistance and hope to improve osteosarcoma chemotherapy sensitivity.
关键词：骨肉瘤抗肿瘤联合化疗方案药物耐受性综述
分类号：R738.1(运动系肿瘤)
资助基金：深圳市知识创新计划基础研究项目(JCYJ20130401112006994)
论文发表日期：2017-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 918-923 )
英文信息